Syros Pharmaceuticals, Inc. · OTC:SYRS
Syros Pharmaceuticals — Technical Presentation (April 2019)
20 slides from Syros Pharmaceuticals's technical presentation, Apr 24, 2019
Slide 1: Key Opinion Leader Symposium on Selective CDK7 Inhibition in Ovarian and Breast Cancers
Key Opinion Leader Symposium on Selective CDK7 Inhibition in Ovarian and Breast Cancers April 24, 2019 Anne Ovarian cancer survivor Exhibit 99.1
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, inc
Slide 3: Company Overview
Company Overview Nancy Simonian, M.D.
Slide 4: Syros today: Clear vision, growing pipeline, pioneering platform
Syros today: Clear vision, growing pipeline, pioneering platform Leading gene control platform Two first-in-class clinical-stage programs Clinical trials in six cancer patient populations Three fast-to-market strategies Multiple data readouts in 2019 and 2020 Experienced leadership team
Slide 5: Pioneering a new approach: Medicines that control the expression of genes
98% Previously unexplored regulatory regions of the genome control the expression of genes determining cell function; majority of disease variation found in these regions Patient Impact Medicines that control the expression of genes to provide a profound benefit for patients with severe diseases Pio
Slide 6: Deep and growing pipeline with multiple potential first-in-class programs
Deep and growing pipeline with multiple potential first-in-class programs SY-1425 is approved in Japan as Amnolake® (tamibarotene) for patients with relapsed/refractory APL * Expected to begin in Q3 2019 Program Indication Drug Discovery IND- Enabling Early Clinical Mid- Clinical Pivotal Commercial
Slide 7: Realizing our vision for the promise of selective CDK7 inhibition
Realizing our vision for the promise of selective CDK7 inhibition in difficult-to-treat cancers Now SY-1365 in multiple ovarian and breast cancer patient populations Opportunities for rapid proof-of concept in high grade serous and clear cell ovarian cancers Next Combination data in earlier lines of
Slide 8: Multiple clinical milestones expected in 2019 and 2020
SY-1425 SY-1365 SY-5609 Three potential proof-of-concept data readouts in 2020 Multiple clinical milestones expected in 2019 and 2020 Q2 2019 Q3 2019 Q4 2019 2020 Complete enrollment in aza combo cohort in biomarker-positive ND unfit AML patients Open new aza combo cohort in R/R biomarker-positive A
Slide 9: Overview of Syros' CDK7 Franchise
Overview of Syros’ CDK7 Franchise David Roth, M.D.
Slide 10: Selective CDK7 inhibition attacks two fundamental processes in cancer
Selective CDK7 inhibition attacks two fundamental processes in cancer Apoptosis Selectively inhibiting CDK7 has been shown preclinically to decrease expression of oncogenic transcription factors and anti-apoptotic proteins Selectively inhibiting CDK7 is thought to interfere with cancer-driving adapt
Slide 11: Exploring SY-1365 as single agent and in combination in ovarian and breast cancer patients
Exploring SY-1365 as single agent and in combination in ovarian and breast cancer patients, including two potential fast-to-market strategies Initial data from relapsed HGSOC and biopsy cohorts expected in Q4 2019, with additional data expected in 2020 Potential proof-of-concept data in clear cell a
Slide 12: SY-1365 demonstrated proof-of-mechanism at tolerable doses in Phase 1 trial
SY-1365 demonstrated proof-of-mechanism at tolerable doses in dose escalation portion of ongoing Phase 1 trial Relative Expression (Log2) 3h post-dose vs. pre-dose SY-1365 Dose (mg/m2) 0 -1 -2 -3 1 4 8 16 32 53 64 80 107 PBMC Gene Expression Signature PBMC CDK7 Occupancy Exceeded desired target occu
Slide 13: SY-1365 demonstrated early evidence of clinical activity
SY-1365 demonstrated early evidence of clinical activity, including durable partial response in relapsed ovarian clear cell cancer patient Clinical activity per RECIST 1.1 criteria observed in 7 of 19 evaluable patients* 1 confirmed PR (clear cell ovarian cancer patient) observed at 80 mg/m2 BIW 6 s
Slide 14: RB pathway alterations predict response to SY-1365 in ovarian cancer PDX models
RB pathway alterations predict response to SY-1365 in ovarian cancer PDX models, pointing to potential biomarker-driven patient enrichment strategy Approximately 2/3 of high-grade serous ovarian cancer patients have RB alterations1 Approximately half of ovarian clear cell cancer patients have delete
Slide 15: SY-1365 shows anti-tumor activity as single agent and in combination in ovarian models
SY-1365 shows anti-tumor activity as single agent and in combination with standard-of-care in ovarian models, supporting ongoing clinical investigation Weekly SY-1365 in combination with carboplatin enhances activity in ovarian cancer xenograft models SY-1365 induces tumor growth inhibition, includi
Slide 16: SY-1365 shows anti-tumor activity and synergy with fulvestrant in HR-positive breast cancer models
SY-1365 shows anti-tumor activity and synergy with fulvestrant in HR-positive breast cancer models, including CDK4/6 inhibitor resistant models Data presented by Syros’ collaborators at Dana-Farber Cancer Institute in December 2018 at San Antonio Breast Cancer Symposium SY-1365 inhibits growth of CD
Slide 17: SY-5609: A potent and highly selective oral CDK7 inhibitor
SY-5609: A potent and highly selective oral CDK7 inhibitor SY-5609 is a potent and highly selective oral CDK7 inhibitor SY-5609 induced apoptosis in cancer cells but not in non-cancerous cells Significant opportunity for adding an oral approach across a range of solid tumors and blood cancers Expect
Slide 18: SY-5609 demonstrates substantial tumor growth inhibition in breast and ovarian cancer models
200 SY-5609 demonstrates substantial tumor growth inhibition as a single agent in multiple breast and ovarian cancer models Triple Negative Breast Cancer CDX Model Ovarian Cancer CDX Model Complete regressions observed in multiple TNBC and ovarian CDX models at doses below the MTD Modulation of down
Slide 19: Key takeaways
Key takeaways Selective CDK7 inhibition represents a potentially transformative targeted approach for many difficult-to-treat cancers SY-1365 is a first-in-class selective CDK7 inhibitor in Phase 1 trial Initial development is focused on ovarian and breast cancers based on mechanistic rationale, pre
Slide 20: SYR=S
SYR=S
Syros Pharmaceuticals — Technical Presentation (April 2019) on 6ix